Compugen (NASDAQ:CGEN) Releases Earnings Results, Beats Expectations By $0.55 EPS

Compugen (NASDAQ:CGEN) issued its quarterly earnings data on Monday. The biotechnology company reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.05 by $0.55, FiscalAI reports. Compugen had a negative net margin of 400.10% and a negative return on equity of 53.60%. The business had revenue of $67.33 million during the quarter, compared to analysts’ expectations of $14.30 million.

Compugen Stock Performance

Shares of NASDAQ CGEN opened at $1.81 on Monday. The firm has a 50 day moving average price of $1.78 and a two-hundred day moving average price of $1.65. Compugen has a 52-week low of $1.13 and a 52-week high of $2.38.

Institutional Trading of Compugen

A number of institutional investors and hedge funds have recently bought and sold shares of CGEN. XTX Topco Ltd acquired a new position in Compugen during the 4th quarter worth about $104,000. Security National Bank of Sioux City Iowa IA acquired a new stake in Compugen during the 4th quarter valued at approximately $38,000. Marshall Wace LLP boosted its stake in shares of Compugen by 135.7% in the 4th quarter. Marshall Wace LLP now owns 106,304 shares of the biotechnology company’s stock valued at $163,000 after purchasing an additional 61,202 shares during the last quarter. State Street Corp raised its stake in Compugen by 3.9% during the fourth quarter. State Street Corp now owns 393,802 shares of the biotechnology company’s stock worth $603,000 after buying an additional 14,701 shares during the last quarter. Finally, Renaissance Technologies LLC grew its holdings in Compugen by 3.7% during the 4th quarter. Renaissance Technologies LLC now owns 1,456,900 shares of the biotechnology company’s stock worth $2,229,000 after acquiring an additional 51,565 shares during the period. 12.22% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on CGEN shares. HC Wainwright started coverage on Compugen in a research report on Wednesday, January 7th. They set a “buy” rating and a $4.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Compugen in a research report on Wednesday, January 21st. Finally, Wall Street Zen raised Compugen from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $4.00.

Compugen Company Profile

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.